Evolus, Inc. (EOLS) |
| 6.5949 0.025 (0.38%) 05-29 15:07 |
| Open: | 6.56 |
| High: | 6.63 |
| Low: | 6.555 |
| Volume: | 421,155 |
| Market Cap: | 434(M) |
| PE Ratio: | -9.99 |
| Exchange: | NASDAQ Global Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.90 |
| Resistance 1: | 6.76 |
| Pivot price: | 6.45 |
| Support 1: | 5.75 |
| Support 2: | 5.11 |
| 52w High: | 10.62 |
| 52w Low: | 3.86 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Financials
| EPS | -0.660 |
| Book Value | -0.440 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.027 |
| Profit Margin (%) | -14.39 |
| Operating Margin (%) | -9.38 |
| Return on Assets (ttm) | -9.1 |
| Return on Equity (ttm) | 0.0 |
Company news
Sat, 23 May 2026
Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily
Thu, 07 May 2026
Evolus, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-05-07 - Seeking Alpha
Mon, 04 May 2026
Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings - Quiver Quantitative
Mon, 04 May 2026
Evolus (NASDAQ: EOLS) grows Q1 2026 sales but remains unprofitable - Stock Titan
Mon, 04 May 2026
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook - Business Wire
Mon, 04 May 2026
Evolus (NASDAQ: EOLS) Q1 2026 earnings, guidance and growth outlook - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
